TENecteplase in Central Retinal Artery Occlusion Stuy (TenCRAOS)

PHASE3CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

June 20, 2025

Study Completion Date

June 20, 2025

Conditions
Central Retinal Artery Occlusion
Interventions
DRUG

Intravenous injection of Tenecteplase and one dose of placebo tablet

Drug: Tenecteplase Tenecteplase administered as an intravenous injection (0.25 mg/kg body weigh; maximum 25 mg)

DRUG

One tablet of Acetylsalicylic Acid and one dose of IV placebo

300 mg Acetylsalisylic acid

Trial Locations (18)

3000

University Hospital Leuven, Leuven

Unknown

University Hospital Antwerp, Antwerp

Aarhus University Hospital, Aarhus

Bispebjerg University Hospital, Copenhagen

Rigshospitalet University Hospital, Copenhagen

Helsinki University Hospital, Helsinki

Turku University Hospital, Turku

Kauno Klinikos Kaunas, Kaunas

Vilnius University Hospital, Vilnius

Haukeland University Hospital, Bergen

Vestre Viken Hospital Trust Drammen, Drammen

Østfold Hospital Trust Kalnes, Dept of Ophthalmology, Grålum

Helse Nord Trøndelag Trust, Namsos

Telemark Hospital Trust, Skien

St Olav University Hospital, Trondheim

Vestfold Hospital Trust, Tønsberg

Karolinska University Hospital, Stockholm

0424

Oslo University Hospital, Oslo

All Listed Sponsors
lead

Oslo University Hospital

OTHER

NCT04526951 - TENecteplase in Central Retinal Artery Occlusion Stuy (TenCRAOS) | Biotech Hunter | Biotech Hunter